Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Role Of P-Glycoprotein And Breast Cancer Resistance Protein-1 In The Brain Penetration And Brain Pharmacodynamic Activity Of The Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

L. Salphati, Leslie B. Lee, Jodie Pang, E. Plise, X. Zhang
Published 2010 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) is a novel small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway currently evaluated in the clinic as an anticancer agent. The objectives of this study were to determine in vitro whether GDC-0941 was a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) and to investigate the impact of these transporters on the pharmacokinetics, brain penetration, and activity of GDC-0941 in FVBn mice (wild-type) and Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)/Bcrp1(−/−) knockout mice. Studies with Madin-Darby canine kidney cells transfected with P-gp or Bcrp1 established that this compound was a substrate of both transporters. After administrations to mice, GDC-0941 brain-to-plasma ratio ranged from 0.02 to 0.06 in the wild-type and Bcrp1(−/−) mice and was modestly higher in the Mdr1a/b(−/−) mice, ranging from 0.08 to 0.11. In contrast, GDC-0941 brain-to-plasma ratio in Mdr1a/b(−/−)/Bcrp1(−/−) triple knockout mice was 30-fold higher than in the wild-type mice. The plasma clearance of GDC-0941 was similar in wild-type and all knockout mice, ranging from 15 to 25 ml/(min · kg) in the wild-type mice and from 18 to 35 ml/(min · kg) in the knockout mice. Exposure after oral administration was comparable in the four strains of mice. The PI3K pathway was markedly inhibited in the brain of Mdr1a/b(−/−)/Bcrp1(−/−) mice for up to 6 h postdose, as evidenced by a 60% suppression of the phosphorylated Akt signal, whereas no inhibition was detected in the brain of wild-type mice. The concerted effects of P-gp and Bcrp1 in restricting GDC-0941 access and pathway modulation in mouse brain may have implications for the treatment of patients with brain tumors.
This paper references
PGlycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan
NA de Vries (2007)
10.1124/dmd.108.024489
The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
L. Zhou (2009)
10.1124/jpet.109.162321
Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
H. Kodaira (2010)
10.1007/s004010000180
Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme
S. Liebner (2000)
10.1007/BF02976689
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
H. Zhang (2003)
10.1586/14737175.6.8.1199
Blood–brain barrier and chemotherapeutic treatment of brain tumors
N. D. de Vries (2006)
10.1016/S1359-6349(09)70416-1
A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.
D. Sarker (2009)
10.1016/S1535-6108(03)00248-4
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
J. Luo (2003)
10.1124/dmd.106.012294
Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios
J. C. Kalvass (2007)
10.1038/nrc2818
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
J. Huse (2010)
10.1093/neuonc/nop058
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
D. Koul (2010)
10.1016/j.ejps.2009.04.001
Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
L. Salphati (2009)
10.1007/s00401-005-1000-1
PIK3CA mutations in glioblastoma multiforme
C. Hartmann (2005)
10.1124/dmd.108.024646
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
J. Polli (2009)
10.1021/jm800295d
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
A. Folkes (2008)
10.1158/1078-0432.CCR-07-1335
P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan
N. D. de Vries (2007)



This paper is referenced by
10.1021/acs.molpharmaceut.7b00277
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Chung-Pu Wu (2017)
10.1021/JM300867C
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.
Timothy Heffron (2012)
10.1002/ijc.28126
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2
F. Li-n (2013)
10.1038/s41568-018-0005-8
Revisiting the role of ABC transporters in multidrug-resistant cancer
R. Robey (2018)
10.1016/j.bcp.2012.01.002
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
K. Natarajan (2012)
Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport
Khine Myint (2015)
10.1021/mp4005595
Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
J. Ware (2013)
10.1093/neuonc/nov164
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Rajneet K. Oberoi (2016)
Regulation of ABCG2 Expression in the Lactating Mammary Gland
A. Wu (2014)
10.1007/978-3-319-23476-2_9
The ABCG2 Multidrug Transporter
Agnès Basseville (2016)
10.1007/978-981-15-3258-0
Bioinspired Biomaterials: Advances in Tissue Engineering and Regenerative Medicine
H. J. Chun (2020)
10.1016/J.GENREP.2017.01.003
Deciphering the molecular signaling pathways in breast cancer pathogenesis and their role in diagnostic and treatment modalities
A. T. Prabha (2017)
10.3109/00498254.2011.603386
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human
L. Salphati (2011)
10.3109/00498254.2014.901585
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole
Y. Nagasaka (2014)
10.2217/cns.13.15
Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
F. Li-n (2013)
Influence of active efflux transport on the distribution of targeted agents to brain tumors
Rajneet K. Oberoi (2014)
10.1007/978-981-15-3258-0_13
Protein-Based Drug Delivery in Brain Tumor Therapy.
Hae Won Hwang (2020)
10.1158/1078-0432.CCR-12-0720
Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
L. Salphati (2012)
10.1021/mp500435s
Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
E. Choo (2014)
10.1124/dmd.114.057513
Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging
L. Salphati (2014)
10.3390/ijms18122544
Obstacles to Brain Tumor Therapy: Key ABC Transporters
J. Wijaya (2017)
10.5772/24940
Breast Cancer from Molecular Point of View: Pathogenesis and Biomarkers
S. Ostad (2011)
10.1002/ijc.29566
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors
P. Zhang (2015)
10.1158/1078-0432.CCR-14-0947
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
D. Sarker (2014)
10.1124/dmd.112.046052
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human
L. Salphati (2012)
10.1016/j.bcp.2020.114137
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Chung-Pu Wu (2020)
Semantic Scholar Logo Some data provided by SemanticScholar